

Osprey Medical Inc. Secondary Trading Notice

Notice given under Section 708A(5)(e) of the Corporations Act

Minnesota, United States and Melbourne, Australia – 11 August 2016. This notice is given by Osprey Medical Inc. (**Osprey**) (ASX:OSP) under section 708(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) (as modified by ASIC Class Order 14/827 (**Class Order**)).

Background

Osprey announced on 4 August 2016 that it had received commitments from sophisticated and institutional investors to subscribe for 100 Million CHES Depositary Interests (**CDIs**) (representing 50 Million shares of Common Stock) at A\$0.28 per CDI to raise approximately A\$28 Million (**Placement**).

Osprey announced that:

- the Placement will be completed in two tranches with Tranche 1 consisting of approximately 38.5 Million CDIs (representing approximately 19.3 Million shares of Common Stock) to be issued within Osprey's 15% placement capacity under ASX Listing Rule 7.1 and its 10% placement capacity under ASX Listing Rule 7.1A; and
- Tranche 2 will consist of approximately 61.5 Million CDIs (representing approximately 30.8 Million shares of Common Stock) to be issued subject to stockholder approval at a special meeting of stockholders to be convened by the Company on or about Tuesday, 30 August 2016.

Osprey has today issued 38,540,000 CDIs (representing 19,270,000 shares of Common Stock) to complete Tranche 1 of the Placement and those CDIs will rank equally with the existing CDIs on issue (**Tranche 1 CDIs**).

Statements by Osprey

Osprey relies on case 1 in section 708A(5) of the Corporations Act (as modified by the Class Order) and gives notice that it has issued the Tranche 1 CDIs without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, Osprey:

- 1 has complied with section 601CK of the Corporations Act and section 674 of the Corporations Act; and

- 2 confirms that, there is no information:
- (a) that has been excluded from a continuous disclosure notice given to ASX in accordance with the ASX Listing Rules; and
 - (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of Osprey; and
 - (ii) the rights and liabilities attaching to Osprey's securities,
 to the extent to which it would be reasonable to investors and their professional advisers to expect to find such information in a disclosure document.

About Osprey

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Media	Investors	Company
Gavin Lower Buchan Consulting T: (613) 8866 1215 glower@buchanwe.com.au	Rebecca Wilson Buchan Consulting M: (61) 417 382 391 rwilson@buchanwe.com.au	Doug Schoenberg VP of Marketing T: (952) 955 8230 dschoenberg@ospreymed.com